Dimolegin
Prevention & Treatment of Thrombosis (COVID-19, Post-surgical, Atrial Fibrillation)
ApprovedActive
Key Facts
Indication
Prevention & Treatment of Thrombosis (COVID-19, Post-surgical, Atrial Fibrillation)
Phase
Approved
Status
Active
Company
About PharmaDiall
PharmaDiall is a private, clinical-stage biotech developing original small molecule therapeutics, with a lead program in anticoagulation. The company's flagship drug, Dimolegin, has completed Phase 3 trials in Russia, demonstrating efficacy in COVID-19-associated thrombosis and showing promise in post-surgical settings. While its initial regulatory and commercial focus appears centered on the Russian market, the company is based in Brussels and targets the multi-billion dollar global anticoagulant market with a potential best-in-class candidate.
View full company profile